Physician profile
Barbara E Mauk
NPI 1285284323
$4,138.77
in general payments reported to CMS, 2019-2025
33 companies · $595 in 2025
The $595 reported for 2025 was more than what 90% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $763 · 2022: $960 · 2023: $1,119 · 2024: $702 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.20 | 2021-2025 | |
| Amgen INC. | $464.80 | 2021-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $410.45 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.16 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Mayne Pharma Commercial LLC | $232.10 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $178.15 | 2023-2025 | Quviviq, Quviviq |
| Amneal Pharmaceuticals LLC | $165.50 | 2021-2025 | Unithroid |
| Exeltis, USA INC. | $146.86 | 2021-2023 | Slynd |
| Millicent US INC | $139.87 | 2021-2025 | Intrarosa, Femring |
| Pfizer INC. | $118.50 | 2022-2023 | |
| Radius Health, INC. | $103.20 | 2023-2025 | Tymlos |
| Biohaven Pharmaceutical Holding Company Ltd. | $84.96 | 2022 | |
| Ascend Therapeutics US, LLC | $76.09 | 2023 | |
| Lilly USA, LLC | $70.63 | 2023-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $69.89 | 2023-2024 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $69.35 | 2021-2022 | |
| Shield Therapeutics INC | $63.90 | 2022-2023 | Accrufer |
| Therapeuticsmd, INC. | $50.22 | 2022 | |
| Davol INC. | $47.36 | 2022-2024 | Arista Ah Flexitip |
| Dexcom, INC. | $45.21 | 2024-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $43.33 | 2022-2023 | Wellbutrin, Aplenzin |
| Biohaven Pharmaceuticals, INC. | $32.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2024 | |
| Coopersurgical, INC. | $29.74 | 2025 | |
| Samsung Hme America, INC. | $28.23 | 2023 | |
| Scynexis, INC. | $23.35 | 2022 | |
| Organon LLC | $21.76 | 2024 | |
| Mycovia Pharmaceuticals, INC. | $20.27 | 2023 | Vivjoa |
| Urovant Sciences INC | $18.26 | 2022 | |
| Avion Pharmaceuticals | $18.12 | 2022 | |
| Sage Therapeutics, LLC | $15.02 | 2025 | Zurzuvae |
| Axonics, INC. | $14.78 | 2022 | |
| Agile Therapeutics, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mauk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.